Literature DB >> 17060123

HLA genotyping is useful in the evaluation of the risk for coeliac disease in the 1st-degree relatives of patients with coeliac disease.

Hannele Karinen1, Päivi Kärkkäinen, Jussi Pihlajamäki, Esko Janatuinen, Markku Heikkinen, Risto Julkunen, Veli-Matti Kosma, Anita Naukkarinen, Markku Laakso.   

Abstract

OBJECTIVE: Coeliac disease (CD) is a common disease with a strong heredity. About 10-20% of 1st-degree relatives of probands develop CD. Relatives should be screened for CD, because if not treated, CD exposes patients to numerous complications. The heterogeneity of symptoms and the lifetime-spanning risk of CD render the timing of CD antibody and/or gastroscopy screenings difficult. As CD susceptibility has been shown to be strongly associated with the HLA alleles DQA1*0501 and DQB1*0201 (together encoding the DQ2 heterodimer) and DRB1*04 (associated with the DQ8 heterodimer), our aim was to investigate whether HLA genotyping might be useful in the identification of 1st-degree relatives of CD patients who do not need further screening for CD.
MATERIAL AND METHODS: The study comprised 54 Finnish CD families including 54 CD probands and 382 living 1st-degree relatives. All subjects who were willing to participate were screened for CD (duodenal and skin biopsies; endomysial, reticulin and gliadin antibodies). The DQA1*0501, DQB1*0201 and DRB1*04 allele frequencies of CD patients and the 1st-degree relatives were determined.
RESULTS: Altogether 17.6% (5.9% of the parents, 15.7% of the siblings, 25.8% of the offspring) of the investigated 1st-degree relatives (n = 245) did not carry any of the alleles studied. All of the CD patients (n = 136) with the exception of one (0.7%) carried at least one of the alleles investigated.
CONCLUSIONS: By using the HLA genotyping a considerable proportion of 1st-degree relatives of CD probands could be excluded from further screening for CD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060123     DOI: 10.1080/00365520600684548

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Predictors of family risk for celiac disease: a population-based study.

Authors:  Alberto Rubio-Tapia; Carol T Van Dyke; Brian D Lahr; Alan R Zinsmeister; Mounif El-Youssef; S Breanndan Moore; Martha Bowman; Lawrence J Burgart; L Joseph Melton; Joseph A Murray
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-30       Impact factor: 11.382

Review 2.  The spectrum of celiac disease: epidemiology, clinical aspects and treatment.

Authors:  Greetje J Tack; Wieke H M Verbeek; Marco W J Schreurs; Chris J J Mulder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03-09       Impact factor: 46.802

Review 3.  Risk factors in familial forms of celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

4.  Clinical utility of celiac disease-associated HLA testing.

Authors:  Kumar Pallav; Toufic Kabbani; Sohaib Tariq; Rohini Vanga; Ciaran P Kelly; Daniel A Leffler
Journal:  Dig Dis Sci       Date:  2014-04-06       Impact factor: 3.199

5.  Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an Australasian perspective.

Authors:  J A Tye-Din; D J S Cameron; A J Daveson; A S Day; P Dellsperger; C Hogan; E D Newnham; S J Shepherd; R H Steele; L Wienholt; M D Varney
Journal:  Intern Med J       Date:  2015-04       Impact factor: 2.048

6.  Carrier frequency of HLA-DQB1*02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening.

Authors:  Dimitri Poddighe; Chiara Rebuffi; Annalisa De Silvestri; Cristina Capittini
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

7.  Late diagnosis of celiac disease in an asymptomatic infant with growth failure.

Authors:  Mauro Bozzola; Elena Bozzola; Sara Pagani; Amelia Mascolo; Rossella Porto; Cristina Meazza
Journal:  Ital J Pediatr       Date:  2014-01-15       Impact factor: 2.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.